Variants

In a trailblazing engineering effort, Canadian and US researchers indicate that the emergence of novel variants of SARS-CoV-2 stems from the mutations of spike glycoprotein that confer either increased affinity for the host cell receptor or increased antibody evasion.//30.8.2021

Tammikuussa Kolumbiasta ensimmäistä kertaa löydetty myy-variantti on viides koronaviruksen muunnos, joka on luokiteltu ”huolta herättäväksi”. WHO:n mukaan tarvitaan lisätutkimusta, ennen kuin tiedetään, onko syytä todelliseen huoleen. //2.9.2021

Koronaviruksen uuden variantin pelätään kykenevän ohittamaan rokotteesta saadun immuniteetin.

Researchers in the USA and China recently published a report in which they discussed the potential factors that confer high infectivity and immune resistance on the Delta and Lambda variants.

A new variant (lineage C.37) initially identified in Lima, Peru, has since been classified as “Lambda” by the World Health Organization (WHO). The lambda variant was classified in June 2021 by the WHO as a “variant of interest.”

Recently, researchers found the risk of being hospitalized was two times higher for people with the Delta variant as compared to those with the Alpha variant.

Researchers have discovered antibodies that prevented SARS-CoV-2 variants in Syrian hamsters and were effective against other coronaviruses.

When the coronavirus copies itself, there is a chance its RNA will mutate. But new variants must jump from one host to another, and the more infections there are, the better chance this will happen.

Scientific Reports - Emergence and expansion of highly infectious...

Nature - Virus-induced senescence is driver and therapeutic target in COVID-19

Viruses accumulate mutations as they replicate in infected cells. Repeated replication can lead to viral strains that show attenuated virulence. Such strains may act as vaccines if the attenuated virus can produce immunity without serious disease.

According to new research by an international team of scientists, all SARS-CoV-2 variants, including variants of concern (VOC) Alpha, Beta, Gamma, and Delta, exhibit enhanced affinity toward recombinant human soluble ACE2.